UPSTREAM BIO INC (UPB) Stock Price & Overview
NASDAQ:UPB • US91678A1079
The current stock price of UPB is 7.67 USD. Today UPB is down by -1.67%. In the past month the price decreased by -73.89%. In the past year, price decreased by -14.21%.
UPB Key Statistics
- Market Cap
- 414.487M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.47
- Dividend Yield
- N/A
UPB Stock Performance
UPB Stock Chart
UPB Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to UPB. When comparing the yearly performance of all stocks, UPB is a bad performer in the overall market: 93.31% of all stocks are doing better.
UPB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UPB. No worries on liquidiy or solvency for UPB as it has an excellent financial health rating, but there are worries on the profitability.
UPB Earnings
On November 5, 2025 UPB reported an EPS of -0.63 and a revenue of 683.00K. The company beat EPS expectations (20.23% surprise) and beat revenue expectations (4.84% surprise).
UPB Forecast & Estimates
12 analysts have analysed UPB and the average price target is 49.47 USD. This implies a price increase of 544.98% is expected in the next year compared to the current price of 7.67.
For the next year, analysts expect an EPS growth of 67.9% and a revenue growth 25.46% for UPB
UPB Groups
Sector & Classification
UPB Financial Highlights
Over the last trailing twelve months UPB reported a non-GAAP Earnings per Share(EPS) of -3.47. The EPS decreased by -99.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.38% | ||
| ROE | -32.43% | ||
| Debt/Equity | 0 |
UPB Ownership
UPB Latest News, Press Relases and Analysis
UPB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16 | 417.437B | ||
| AMGN | AMGEN INC | 16.31 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.27 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.6 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.84 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.36 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.24 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 308.82 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About UPB
Company Profile
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The company has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
Company Info
UPSTREAM BIO INC
890 Winter Street, Suite 200
Waltham MASSACHUSETTS US
Employees: 52
Phone: 17812082466
UPSTREAM BIO INC / UPB FAQ
What does UPB do?
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The company has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
What is the current price of UPB stock?
The current stock price of UPB is 7.67 USD. The price decreased by -1.67% in the last trading session.
What is the dividend status of UPSTREAM BIO INC?
UPB does not pay a dividend.
How is the ChartMill rating for UPSTREAM BIO INC?
UPB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for UPB stock?
12 analysts have analysed UPB and the average price target is 49.47 USD. This implies a price increase of 544.98% is expected in the next year compared to the current price of 7.67.
Is UPSTREAM BIO INC (UPB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on UPB.